{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:06:26Z","timestamp":1793070386636,"version":"4.5.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is widely appreciated. However, there is limited knowledge regarding the potential impact of SARS-CoV-2 vaccines on the thyroid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed two prospective clinical trials between April and June, 2021, enrolling recipients of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV and CoronaVac). Thyroid function, antithyroid antibody levels, and SARS-CoV-2 neutralizing antibody levels were detected for each participant before receiving the first vaccine dose and 28 days after receiving the second vaccine dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 657 recipients participated in the study. The overall median thyroid function and levels of antithyroid antibodies before and after SARS-CoV-2 vaccination were within the normal range. Among the 564 participants with normal thyroid function at baseline, 36 (6.38% [confidence interval; CI 4.51\u20138.73]) developed thyroid dysfunction. Of the 545 recipients with negative antithyroid antibodies at baseline, none developed abnormal antibodies after vaccination. Notably, 75.27% (70\/93 [CI 65.24\u201383.63]) of the 93 recipients with thyroid dysfunction returned to normal function after vaccination. The levels of antithyroid peroxidase antibody (96.20% [CI 89.30\u201399.21]) and antithyroglobulin antibody (TgAb; 88.31% [CI 78.97\u201394.51]) remained positive after vaccination in most patients with abnormal values at baseline. However, the TgAb levels in more than half of the patients (48\/77) decreased. All of 11 abnormal thyrotropin receptor antibody levels at baseline decreased postvaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Vaccination with an inactivated SARS-CoV-2 vaccine had no significant adverse impact on thyroid function or antithyroid antibodies within the first 28 days after the second dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration:<\/jats:title>\n                    <jats:p>ChiCTR2100045109 and ChiCTR2100042222.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2022.0101","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T02:07:30Z","timestamp":1658455650000},"page":"1051-1058","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Inactivated SARS-CoV-2 Vaccine on Thyroid Function and Autoimmunity Within 28 Days After the Second Dose"],"prefix":"10.1177","volume":"32","author":[{"given":"Liubing","family":"Li","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Trials Unit; Guangzhou, People's Republic of China."},{"name":"Department of Institute of Precision Medicine; The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs; Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Guangzhou, People's Republic of China."},{"name":"Department of Clinical Trials Unit; Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohui","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Clinical Trials Unit; Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Institute of Precision Medicine; The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Clinical Trials Unit; Guangzhou, People's Republic of China."},{"name":"Department of Institute of Precision Medicine; The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Guangzhou, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"WHO Coronavirus (COVID-19) Dashboard. Available from: https:\/\/covid19.who.int [Last accessed: July 6 2022]."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30843-4"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","unstructured":"Xia S Zhang Y Wang Y et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine BBIBP-CorV: A randomised double-blind placebo-controlled phase 1\/2 trial. Lancet Infect Dis 2021;21(1):39\u201351; doi: 10.1016\/S1473-3099(20)30831-8.","DOI":"10.1016\/S1473-3099(20)30831-8"},{"key":"e_1_3_5_5_2","unstructured":"Side Effects of COVID-19 Vaccines. Available from: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/side-effects-of-covid-19-vaccines [Last accessed: July 6 2022]."},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","unstructured":"Franquemont S Galvez J. Subacute thyroiditis after mRNA vaccine for Covid-19. J Endocr Soc 2021;5(Suppl 1):A956\u2013A957.","DOI":"10.1210\/jendso\/bvab048.1954"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","unstructured":"Iremli BG Sendur SN Unluturk U. Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: Postvaccination ASIA Syndrome. J Clin Endocrinol Metab 2021;106(9):2600\u20132605; doi: 10.1210\/clinem\/dgab373.","DOI":"10.1210\/clinem\/dgab373"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","unstructured":"Leber HM Sant'Ana L Konichi da Silva NR et al. Acute thyroiditis and bilateral optic neuritis following SARS-CoV-2 vaccination with CoronaVac: A case report. Ocul Immunol Inflamm 2021;29(6):1200\u20131206; doi: 10.1080\/09273948.2021.1961815.","DOI":"10.1080\/09273948.2021.1961815"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","unstructured":"Oyibo SO. Subacute thyroiditis after receiving the adenovirus-vectored vaccine for coronavirus disease (COVID-19). Cureus 2021;13(6):e16045; doi: 10.7759\/cureus.16045.","DOI":"10.7759\/cureus.16045"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","unstructured":"Patel KR Cunnane ME Deschler DG. SARS-CoV-2 vaccine-induced subacute thyroiditis. Am J Otolaryngol 2022;43(1):103211; doi: 10.1016\/j.amjoto.2021.103211.","DOI":"10.1016\/j.amjoto.2021.103211"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","unstructured":"Sahin Tekin M Saylisoy S Yorulmaz G. Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: A case report. Hum Vaccin Immunother 2021;17(11):4090\u20134092; doi: 10.1080\/21645515.2021.1947102.","DOI":"10.1080\/21645515.2021.1947102"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","unstructured":"Patrizio A Ferrari SM Antonelli A et al. A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun 2021;125:102738; doi: 10.1016\/j.jaut.2021.102738.","DOI":"10.1016\/j.jaut.2021.102738"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","unstructured":"Vera-Lastra O Ordinola Navarro A Cruz Domiguez MP et al. Two cases of Graves' disease following SARS-CoV-2 vaccination: An autoimmune\/inflammatory syndrome induced by adjuvants. Thyroid 2021;31(9):1436\u20131439; doi: 10.1089\/thy.2021.0142.","DOI":"10.1089\/thy.2021.0142"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","unstructured":"Zettinig G Krebs M. Two further cases of Graves' disease following SARS-Cov-2 vaccination. J Endocrinol Invest 2022;45(1):227\u2013228; doi: 10.1007\/s40618-021-01650-0.","DOI":"10.1007\/s40618-021-01650-0"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","unstructured":"Murvelashvili N Tessnow A. A case of hypophysitis following immunization with the mRNA-1273 SARS-CoV-2 vaccine. J Investig Med High Impact Case Rep 2021;9:23247096211043386; doi: 10.1177\/23247096211043386.","DOI":"10.1177\/23247096211043386"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","unstructured":"Ross DS Burch HB Cooper DS et al. 2016 American Thyroid Association Guidelines for Diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26(10):1343\u20131421; doi: 10.1089\/thy.2016.0229.","DOI":"10.1089\/thy.2016.0229"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","unstructured":"Garber JR Cobin RH Gharib H et al. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012;22(12):1200\u20131235; doi: 10.1089\/thy.2012.0205.","DOI":"10.1089\/thy.2012.0205"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","unstructured":"Shoenfeld Y Agmon-Levin N. \u2018ASIA\u2019\u2014Autoimmune\/inflammatory syndrome induced by adjuvants. J Autoimmun 2011;36(1):4\u20138; doi: 10.1016\/j.jaut.2010.07.003.","DOI":"10.1016\/j.jaut.2010.07.003"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","unstructured":"Bragazzi NL Hejly A Watad A et al. ASIA syndrome and endocrine autoimmune disorders. Best Pract Res Clin Endocrinol Metab 2020;34(1):101412; doi: 10.1016\/j.beem.2020.101412.","DOI":"10.1016\/j.beem.2020.101412"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","unstructured":"Watad A David P Brown S et al. Autoimmune\/inflammatory syndrome induced by adjuvants and thyroid autoimmunity. Front Endocrinol (Lausanne) 2016;7:150; doi: 10.3389\/fendo.2016.00150.","DOI":"10.3389\/fendo.2016.00150"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","unstructured":"Kanduc D Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: Implications for the vaccine. Immunol Res 2020;68(5):310\u2013313; doi: 10.1007\/s12026-020-09152-6.","DOI":"10.1007\/s12026-020-09152-6"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","unstructured":"Dotan A Muller S Kanduc D et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021;20(4):102792; doi: 10.1016\/j.autrev.2021.102792.","DOI":"10.1016\/j.autrev.2021.102792"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","unstructured":"Segal Y Shoenfeld Y. Vaccine-induced autoimmunity: The role of molecular mimicry and immune crossreaction. Cell Mol Immunol 2018;15(6):586\u2013594; doi: 10.1038\/cmi.2017.151.","DOI":"10.1038\/cmi.2017.151"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","unstructured":"Lui DTW Lee CH Cheung CYY et al. Impact of COVID-19 vaccines on thyroid function and autoimmunity and impact of thyroid autoimmunity on antibody response. J Clin Endocrinol Metab 2022; doi: 10.1210\/clinem\/dgac355.","DOI":"10.1210\/clinem\/dgac355"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","unstructured":"Paschou SA Karalis V Psaltopoulou T et al. Patients with autoimmune thyroiditis present similar immunological response to COVID-19 BNT162b2 mRNA vaccine with healthy subjects while vaccination may affect thyroid function: A clinical study. Front Endocrinol (Lausanne) 2022;13:840668; doi: 10.3389\/fendo.2022.840668.","DOI":"10.3389\/fendo.2022.840668"},{"key":"e_1_3_5_26_2","unstructured":"COVID-19 Vaccine Frequently Asked Questions: Frequently Asked Questions. Available from: https:\/\/www.thyroid.org\/covid-19\/coronavirus-frequently-questions\/ [Last accessed: July 6 2022]."},{"key":"e_1_3_5_27_2","unstructured":"European Society of Endocrinology (ESE)'s statement concerning COVID-19 vaccination: \u2018follow the same recommendations for patients with stable endocrine disorders as for the general population\u2019. Available from: https:\/\/www.ese-hormones.org\/news\/ese-news\/european-society-of-endocrinology-ese-s-statement-concerning-covid-19-vaccination-follow-the-same-recommendations-for-patients-with-stable-endocrine-disorders-as-for-the-general-population [Last accessed: July 6 2022]."},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","unstructured":"Mitsunaga T Ohtaki Y Seki Y et al. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: A prospective study in Japan. PeerJ 2021;9:e12316; doi: 10.7717\/peerj.12316.","DOI":"10.7717\/peerj.12316"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","unstructured":"Pellini R Venuti A Pimpinelli F et al. Initial observations on age gender BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine 2021;36:100928; doi: 10.1016\/j.eclinm.2021.100928.","DOI":"10.1016\/j.eclinm.2021.100928"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","unstructured":"Tretyn A Szczepanek J Skorupa M et al. Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination. Cells 2021;10(8):1952; doi: 10.3390\/cells10081952.","DOI":"10.3390\/cells10081952"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","unstructured":"Van Loveren H Van Amsterdam JG Vandebriel RJ et al. Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors. Environ Health Perspect 2001;109(8):757\u2013764; doi: 10.1289\/ehp.01109757.","DOI":"10.1289\/ehp.01109757"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2022.0101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2022.0101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2022.0101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:09:21Z","timestamp":1777586961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2022.0101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1089\/thy.2022.0101"],"URL":"https:\/\/doi.org\/10.1089\/thy.2022.0101","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}